24 research outputs found
Perceived norms about the acceptability of intimate partner violence, adjusted estimates by survey condition, using partial proportional odds regression (<i>n =</i> 1,334).
<p>Perceived norms about the acceptability of intimate partner violence, adjusted estimates by survey condition, using partial proportional odds regression (<i>n =</i> 1,334).</p
Perceived norms about the acceptability of intimate partner violence, unadjusted estimates by survey condition (<i>n =</i> 1,334).
<p>Perceived norms about the acceptability of intimate partner violence, unadjusted estimates by survey condition (<i>n =</i> 1,334).</p
Characteristics of the sample (<i>n =</i> 1,334).
<p>Characteristics of the sample (<i>n =</i> 1,334).</p
Personal beliefs about the acceptability of intimate partner violence, unadjusted estimates by survey condition (<i>n =</i> 1,334).
<p>Personal beliefs about the acceptability of intimate partner violence, unadjusted estimates by survey condition (<i>n =</i> 1,334).</p
Subgroup analysis of differences in ordinal scale at days 28–35.
Estimated proportional odds ratios comparing day 28–35 ordinal scale in HCQ/CQ versus control groups. Estimates are given for the pooled patient population and for subgroups. Blue circles represent model-standardized estimates; blue horizontal lines represent 95% credible intervals. Open grey circles represent plug-in estimates; grey horizontal lines represent 95% confidence intervals. Grey circle size represents the number of patients in the corresponding subgroup. Arrows indicate uncertainty intervals extending beyond plot limits. Study acronyms are explained in Fig 1. Two trials did not have study acronyms (only trial registration numbers). Abbreviations: 95% CrI, 95% credible intervals; HCQ/CQ, hydroxychloroquine or chloroquine; NA, not applicable; NIV, noninvasive ventilation (includes BiPAP/CPAP and/or high-flow oxygen); OR, odds ratio.</p
Trial characteristics: Treatment groups, participant assessment, and inclusion/exclusion criteria.
(PDF)</p
Trial selection process.
aTwo of the trials did not have study acronyms (only trial registration numbers). Abbreviations: COVID MED, Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic; HAHPS, Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19; OAHU-COVID19, A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients; ORCHID, Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease; TEACH, Treating COVID-19 With Hydroxychloroquine; WU352, Washington University 352: Open-label, Randomized Controlled Trial of Hydroxychloroquine Alone or Hydroxychloroquine Plus Azithromycin or Chloroquine Alone or Chloroquine Plus Azithromycin in the Treatment of SARS CoV-2 Infection.</p
Primary, secondary, and safety outcomes, overall and by trial.
Primary, secondary, and safety outcomes, overall and by trial.</p